Abstract
AbstractComorbidities impair the prognosis of diffuse large B-cell lymphoma (DLBCL). Type 2 diabetes mellitus (DMT2) increases the risk of other comorbidities, e.g., heart failure (HF). Thus, we hypothesized that pre-existing DMT2 may negatively affect the outcome of DLBCL. To verify this, DLBCL patients treated with (R)-CHOP were enrolled. 469 patients were eligible, with a median age of 57 years; 356 patients had advanced-stage DLBCL. 126 patients had high-intermediate and 83 high-risk international prognostic index (IPI). Seventy-six patients had DMT2, 46 HF; 26 patients suffered from both DMT2 and HF. In the analyzed group DMT2 or HF significantly shortened overall survival (OS) and progression free survival (PFS): the 5-year OS for patients with DMT2 was 64% vs 79% and for those with HF: 49% vs 79%. The 5-year PFS for DMT2 was 50.6% vs 62.5% and for HF 39.4% vs 63.2%. The relapse/progression incidence was comparable between groups; the non-relapse/progression mortality (NRPM) was significantly higher solely in DMT2 patients (5-year NRPM 22.5% vs 8.4%). The risk of death was higher in patients with higher IPI (HR = 1.85) and with DMT2 (HR = 1.87). To conclude, pre-existing DMT2, in addition to a higher IPI and HF, was a negative predictor for OS and PFS.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Terret, C., Albrand, G., Rainfray, M. & Soubeyran, P. Impact of comorbidities on the treatment of non-Hodgkin’s lymphoma: a systematic review. Expert. Rev. Hematol. 8, 329–341, https://doi.org/10.1586/17474086.2015.1024650 (2015).
2. van der Poel, M. W. et al. Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study. Ann. Hematol. 94, 1373–1379, https://doi.org/10.1007/s00277-015-2358-3 (2015).
3. Moser, E. C. et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 107, 2912–2919, https://doi.org/10.1182/blood-2005-08-3392 (2006).
4. Haddy, T. B. et al. Late effects in long-term survivors of high-grade non-Hodgkin’s lymphomas. J. Clin. oncology: Off. J. Am. Soc. Clin. Oncol. 16, 2070–2079, https://doi.org/10.1200/JCO.1998.16.6.2070 (1998).
5. Jurczak, W. et al. Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - A national multicenter study. Int J Cardiol, doi:S0167-5273(13)01558-1 (2013).
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献